Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, ...
Danaher is undervalued, with strong fundamentals, robust free cash flow, and a "Buy" rating targeting $210 (12.7% upside). DHR's bioprocessing segment drives growth, balancing Life Sciences weakness, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback